Skip to main navigation

Immunocore

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Financials & Filings
- SEC Filings
- Annual Reports
IR Resources

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Financials & Filings
- SEC Filings
- Annual Reports
IR Resources

News Releases

Breadcrumb

Home /
Investor Relations /
News & Events /
News Releases

Year

2 December 2022

Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors

23 November 2022

Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference

11 November 2022

Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting

10 November 2022

Immunocore to present at the Jefferies London Healthcare Conference

9 November 2022

Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update

9 September 2022

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress

10 August 2022

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update

3 August 2022

Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022

1 August 2022

Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

18 July 2022

Immunocore Announces $140 Million Private Placement Financing

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 21 - 30 of 174

Site - Shareholder Tools

Immunocore

Site - Footer Social

About us
Our science
Our therapy areas
For patients

News
Careers
Contact us

Privacy and Social Media Guidelines
Cookies
Payments and Disclosures
Clinical trials

©2023 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd